Today: 10 June 2026
Browse Category

NASDAQ:HUMA 12 November 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte reported Q3 revenue of $753,000, with $703,000 from Symvess sales, and a net loss of $17.5 million (GAAP EPS −$0.11). The company said 25 Value Analysis Committee approvals now cover 92 U.S. hospitals, with 16 hospitals ordering Symvess. Positive two-year Phase 3 dialysis trial results were presented, and an IND was submitted for a coronary bypass graft study in 2026.
12 November 2025
··

Stock Market Today

  • Market Crash May Offer Rare Buying Opportunity for FTSE 100 Dividend Stocks
    June 10, 2026, 1:50 PM EDT. Global markets, including the FTSE 100, are under pressure amid renewed Middle East tensions and surging crude oil prices, sparking fears of a market downturn. The tech sector faces volatility due to the AI bubble burst and supply chain disruptions linked to Korean suppliers. This environment may present a once-in-a-decade chance for investors to purchase undervalued, reliable dividend stocks. Legal & General (LSE: LGEN), with the highest dividend yield on the FTSE 100, remains near 2016 price levels despite overall index gains. Strong recent profits and a robust solvency ratio underscore its resilience. While risks from geopolitical and tariff issues persist, the current market dip could offer long-term gain potential as recovery unfolds.

Latest articles

MARA Shares Drop as Miner Selloff Hits Bitcoin-Linked Stocks

MARA Shares Drop as Miner Selloff Hits Bitcoin-Linked Stocks

10 June 2026
MARA Holdings shares slid 3.9% to $12.79, underperforming Bitcoin’s rebound above $62,000, as investors repriced crypto miners amid tech stock weakness, high energy costs, and sector-wide pressure; MARA’s future now hinges on its pivot toward power infrastructure and AI, with its $1.5B Long Ridge Energy deal pending regulatory approval and Bitcoin price swings still driving revenue and massive quarterly losses.
UiPath Stock Moves Higher, but ARR Growth Stays in Focus for PATH

UiPath Stock Moves Higher, but ARR Growth Stays in Focus for PATH

10 June 2026
UiPath shares edged up 1% to $10.87 after Tuesday’s 3.76% drop, as investors focus on slowing ARR growth; the company guided Q2 ARR to $1.929–$1.934 billion, below last quarter’s $49 million net new ARR, leaving Wall Street cautious despite first-ever GAAP profitability and a new $500 million buyback.
BigBear.ai Stock Bounces as Shareholder Vote Squeeze Meets Panama AI Speculation

BigBear.ai Stock Bounces as Shareholder Vote Squeeze Meets Panama AI Speculation

10 June 2026
BigBear.ai shares rose 2.8% to $4.10 as investors weighed the approved move to double authorized shares to 1 billion, giving the company flexibility for financing but raising dilution risks, while the Panama cargo-security rollout and $281.9 million backlog keep growth hopes alive amid ongoing losses and revenue conversion questions.
Go toTop